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Summary 
 
A total of 454 pigs (21 d of age, 13.4 lb) 
were used in a 130-d field study to investigate 
porcine circovirus type 2 (PCV2) vaccine ef-
fects on growth performance of boars and gilts 
of 4 different genetic backgrounds: A×A (Du-
roc-based sire and dam), B×B (synthetic line 
sire and dam lines derived from Duroc, Pie-
train, and Large White), A×B, and B×A. 
 
Pigs were identified as potential test pigs 
at birth and ear tagged for identification. Cha-
racteristics including litter, genetic back-
ground, gender, and birth weight were re-
corded and used in allotting PCV2 vaccine 
treatment groups. Pigs were vaccinated ac-
cording to label dose with a 2-dose commer-
cial PCV2 vaccine (Circumvent PCV, Intervet 
Inc., Millsboro, DE) at weaning (d 0) and 
again 14 d later. Vaccinated and control pigs 
were comingled within the same pen for the 
duration of the study. Pigs were individually 
weighed on d 0, 40, and 130 to measure 
growth rate. Backfat and loin depth were 
measured on d 130 by using real-time ultra-
sound. Blood was collected on d 0, 40, and 
130 for indirect fluorescent antibody meas-
urement of PCV2 antibodies and polymerase 
chain reaction (PCR) analysis for determina-
tion of PCV2 virus load.  
By d 130, vaccinates were heavier (P < 
0.01) than controls. However, the magnitude 
of the weight difference between control and 
vaccinates was almost 4 times greater in the 
A×A pigs than in the B×B pigs (P < 0.05).  
On the basis of growth performance, the dif-
ferent genetic backgrounds responded differ-
ently to the PCV2 vaccination even though 
they were comingled in the same pen. In the 2 
pure-line populations, even the best perform-
ing portion of the population appeared to ben-
efit from vaccination, suggesting that growth 
performance of most pigs is being affected by 
PCV2 infection.  
 
Control pigs exhibited a late increase in 
PCV2 antibody levels, a consequence of natu-
ral infection. In contrast, vaccinated pigs did 
not exhibit a late-finisher antibody rise. Vac-
cinated pigs possessed a decreased viral load 
(as quantified by PCR PCV2 viral DNA) at 
both d 40 and 130. The data demonstrate that 
genetic background affects either the expres-
sion of porcine circoviral disease or the re-
sponse to the PCV2 vaccine.  
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Introduction 
 
The primary agent of porcine circoviral 
disease (PCVD) is porcine circovirus type 2 
(PCV2). The approved case definition for 
PCVD defines a PCVD herd as one which 
demonstrates one or more of the following 
clinical manifestations: wasting, respiratory or 
enteric signs, high mortality, porcine dermati-
tis and nephropathy syndrome, or reproductive 
disorders. Porcine circoviral disease is con-
firmed by finding microscopic lesions consis-
tent with the disease in affected pigs as well as 
the presence of viral antigen in tissues.  
 
Reported risk factors associated with 
PCVD include litter of origin, management 
factors, and gender as well as genetics. Only 
limited, controlled research has been com-
pleted to define the role of these risk factors in 
the development and expression of PCVD and 
response to vaccination. The focus of this 
study was to further elucidate the contribution 
of genetic background to PCVD by comparing 
the response of different genetic lines of pigs 
to PCV2 vaccination in a high-health herd 
with naturally circulating PCV2. 
 
Procedures 
 
A 1,700-sow multiplier farm in Kansas 
was used for this field study. This single-site 
farm maintains a high-health status; it is por-
cine reproductive and respiratory syndrome 
virus negative and without evidence of My-
coplasma hyopneumoniae infection since its 
stocking in 2000. Despite the high-health sta-
tus, the presence of PCV2b virus had been do-
cumented in this herd. However, the primary 
concern was an increase in morbidity charac-
terized by ill-thrift and slow growing pigs as 
mortality was within the expected historic 
range on this farm.  
 
For this 130-d study, a total of 454 pigs 
from 4 genetic backgrounds were ranked by 
birth weight within litter and gender (boar or 
gilt) and randomly assigned to PCV2 vaccine 
treatment group (vaccinated or nonvaccinated 
control). Birth weight was balanced across 
vaccine treatment. Genetic background in-
cluded pure lines of A×A (Duroc-based sire 
and dam) and B×B (synthetic line for the sire 
and dam primarily derived from Duroc, Pie-
train, and Large White) and crossbreds A×B 
and B×A.  
 
Vaccine treatment pigs were vaccinated 
intramuscularly with a 2-dose commercial 
PCV2 vaccine (Circumvent PCV, Intervet Inc, 
Millsboro, DE) according to label dose at 21 
and 35 d of age. Vaccinated pigs were comin-
gled with nonvaccinated control pigs for the 
duration of the trial. 
 
Pigs were individually weighed and bled 
at birth, weaning (d 0), end of nursery (d 40), 
and off test (d 130). Loin depth and backfat 
measurements were collected by using real-
time ultrasound on d 130.  
 
Removals and deaths were recorded dur-
ing all phases. There were 6 deaths in the nur-
sery phase, 25 deaths in the finisher phase, 
and 6 other records removed because of data 
entry errors or unrelated physical defects. Data 
analysis was performed on the 417 pigs that 
had complete growth records. 
 
Comparisons between vaccinates and non-
vaccinated controls, genetic background, and 
gender were made in a 2 × 4 × 2 factorial 
treatment design. Litter of origin was managed 
as a random effect. Statistical analysis was 
performed by using the Proc GLIMMIX pro-
cedure of SAS to obtain least square means 
and standard errors for the response criteria. 
  
Results 
 
Despite active PCV2 infection, there was 
no discernable pattern of mortality among the 
genetic backgrounds, and overall mortality 
was similar between vaccinates (6.8%) and 
controls (7.0%). There were no 3-way gender 
× genetic background × vaccine interactions 
found for the response criteria in this study 
with the exception of backfat depth after 
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weight adjustment. The significant interaction 
(P = 0.02) was the result of control A×B cros-
sbred boars having a higher weight-adjusted 
backfat depth than vaccinated A×B crossbred 
boars (11.9 ± 0.4 mm for controls vs. 10.9 ± 
0.4 mm for vaccinates). Within all other gen-
der by genetic background combinations, 
backfat depth was similar between controls 
and vaccinates.  
 
Weaning age and weight and off-test age 
were not different for the vaccine × genetic 
background least squares means (Table 1). A 
vaccine × genetic background interaction was 
noted for nursery ADG, finisher ADG, and 
overall wean-to-finish ADG (P = 0.05, P = 
0.05, and P = 0.04, respectively). In the nurs-
ery phase, this interaction was due to the A×B 
vaccinates having lower (P = 0.04) ADG than 
A×B controls. In contrast, B×A and B×B vac-
cinates had numerically higher ADG than con-
trols. For the A×A pigs, controls and vacci-
nates had similar ADG. Therefore, in the 
nursery period of this study, genetic back-
ground did affect how vaccinates performed 
compared with controls; controls demon-
strated higher nursery ADG in a single genetic 
background, whereas in the other lines, there 
was little to no performance difference be-
tween vaccinates and controls. Although the 
interaction was statistically significant, we are 
unsure of the biologic significance. In the fin-
isher phase of production, ADG was lower (P 
< 0.01) for the A×A controls than for the con-
trol pigs of A×B, B×A, and B×B. In contrast, 
A×A vaccinates had similar ADG to all 
groups except A×B (P = 0.04). Thus, the 
magnitude of the difference between control 
and vaccinate groups was greater for the A×A 
pigs than for B×B and crossbred pigs. Wean-
to-finish ADG followed a pattern similar to 
that of finisher ADG. 
 
At d 130, A×A control pigs weighed less 
(P < 0.01) than controls from the other 3 ge-
netic backgrounds, whereas A×A vaccinates 
weighed less (P = 0.04) than B×A vaccinates.  
 
Prior to adjusting backfat and loin depths 
to a common off-test weight, it appeared there 
were significant differences in loin depth and 
numerical differences in backfat measurement 
between vaccine treatment groups. After ad-
justment, there was a genetic background ef-
fect (P < 0.01) for loin depth as well as a 3-
way gender × genetic background × vaccine 
interaction (P = 0.02) for backfat measure-
ment. Despite the 3-way interaction for back-
fat depth, there was no significant effect of 
vaccination on backfat (P = 0.62) or loin 
depth (P = 0.29) after adjustment to a com-
mon off-test weight.  
 
Indirect fluorescent antibody analysis 
demonstrated antibody responses to both vac-
cine and natural PCV2 exposure (Figure 1). In 
response to vaccination, vaccinates had in-
creased (P < 0.01) antibody production by d 
40 compared with controls, but as a result of 
natural PCV2 exposure, controls demonstrated 
a rise (P < 0.01) in antibody levels compared 
with vaccinates by d 130. PCV2 DNA tem-
plate copies per reaction provided an estimate 
of viral load (Figure 2). PCV2 vaccination re-
duced mean viral load in vaccinates compared 
with controls at both d 40 (P < 0.01) and 130 
(P < 0.01) 
 
Discussion 
 
The results from this study demonstrate 
that genetic background affects response to 
PCV2 vaccination or PCVD expression as 
measured by growth rate. The findings in this 
study are unique because this herd did not fit 
the accepted case definition for PCVD; yet, 
this study clearly demonstrates that PCV2 
vaccination improved the growth performance 
of vaccinated pigs compared with controls. 
 
The difference in magnitude of the finisher 
ADG and wean-to-finish ADG was 3 and 5 
times greater, respectively, in A×A pigs than 
in B×B pigs. In addition, within each cross-
bred genetic background, vaccinated pigs con-
sistently had numerically increased ADG 
compared with controls. Vaccinated pigs were 
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19.7, 6.2, 10.2, and 5.0 lb heavier compared 
with nonvaccinated controls for A×A, A×B, 
B×A, and B×B genetic backgrounds, respec-
tively. Similar to other studies we have con-
ducted, PCV2-vaccinated pigs demonstrated 
increased growth rate during the finisher 
phase. However, the magnitude of the weight 
difference was almost 4 times greater in the 
A×A pigs than in the B×B pigs. Although the 
B×B pigs grew faster than the A×A pigs, they 
had a similar overall pattern of weight distri-
bution about their means. There is a right shift 
in the off-test weights of vaccinates compared 
with controls in each population (Figures 3 
and 4). This indicates that within each of these 
genetic backgrounds, all the vaccinated pigs 
had increased growth rate. Even in apparently 
clinically unaffected pigs, the PCV2 virus ap-
pears to affect growth rate. 
 
Carcass composition was not affected by 
vaccination in this study after adjusting for 
off-test weight. Genetic background, however, 
did affect carcass traits. Pigs from the Duroc-
based lines had decreased loin depth and in-
creased backfat compared with pigs from the 
Duroc-, Pietrain-, and Large White-based 
lines.  
 
There was a clear rise in antibody produc-
tion by d 40 due to vaccination as indicated by 
the higher PCV2 antibody titers in the vacci-
nates compared with controls. A rise in anti-
body titer in the control pigs from d 40 to 130 
indicated active PCV2 infection due to field 
virus exposure during the trial period. In con-
trast, vaccinates had a decrease in PCV2 anti-
body titer from d 40 to 130, which suggests 
that vaccinates have increased resistance to 
infection. The results of this study support 
previous research findings that PCV2 vaccina-
tion effectively decreases viral load, even un-
der comingled conditions. Controls had a lar-
ger quantity of viral templates per reaction 
compared with vaccinates at d 40. By d 130, 
the difference between the treatment groups 
remained; however, mean template copies per 
reaction were reduced to 3.8 for controls com-
pared with 1.3 for vaccinates. The biologic 
significance of these viral load quantities re-
mains to be determined; however, the poten-
tial for the PCV2 vaccine to aid in the reduc-
tion of viremia and viral shedding is apparent.  
 
The data in this study demonstrate that ge-
netic background affects either the expression 
of PCVD or the response to the PCV2 vac-
cine, as measured by growth performance. 
Therefore, genetic background should be con-
sidered a risk factor for expression of PCVD 
or a factor that affects response to PCV2 vac-
cine.  
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Table 1.  Effect of PCV2 vaccine treatment and genetic background on ages, weights, growth rates, and carcass characteristics1
 Genetic background2
 A × A  A × B  B × A  B × B 
Item Control3 Vacc.  Control Vacc.  Control Vacc.  Control Vacc. SE4
Vaccine × Genetic
Probability, P < 
no. of pigs 62 55 60 65 34 32 55 54   
A   ge, d           
Weaning 21.2 21.1 20.3 20.3 21.3 21.3 19.7 19.6 0.6 0.71 
Off test 151.5 151.4 150.6 150.6 151.7 151.7 150.0 150.0 0.7 0.41 
Weaning weight, lb 
, lb
12.8 13.5 13.8 13.9 14.5 14.2 12.8 13.2 0.7 0.51 
ADG4             
Nursery phase  0.84a 0.85abc 0.96bd 0.90ace 0.96bcde 1.02de 0.92abcde 0.88abc 0.05 0.05 
Finisher phase 1.70a 1.91b 1.93b 2.02c 1.91bc 2.00bc 1.88b 1.95bc 0.05 0.05 
Wean-to-finish 1.44a 1.59b 1.63bc 1.68bc 1.63b 1.71c 1.60bc 1.60bc 0.05 0.04 
Off-test weight, lb 200.9a 220.6b 226.7bc 232.9bc 226.7bc 236.9c 220.7b 225.7bc 6.5 0.05 
Carcass characteristics, mm          
Backfat depth 11.4 12.0 12.1 12.0 11.2 11.7 10.6 10.8 0.5 0.46 
Loin depth 59.2 62.2 65.7 66.9 66.3 69.0 68.8 69.6 1.3 0.32 
Backfat depth  
(weight adjusted) 12.2 12.1 11.9 11.6 11.1 11.2 10.7 10.7 0.5 0.79 
Loin depth  
(weight adjusted) 62.3 62.6 65.1 65.4 65.8 67.1 69.2 69.2 0.9 0.82 
Note. Results reported as least squares means.  
abcde Within a row, means without a common superscript letter differ (P < 0.05). 
1 A total of 454 pigs from 4 genetic backgrounds were assigned to vaccine treatment by ranking them by weight within litter and gender and ran-
domly assigning each pig to either vaccine or nonvaccinate control, balanced by birth weight across vaccine treatment. Pigs were individually 
weighed at birth, weaning (d 0), end of nursery (d 40), and off test (d 130). Backfat and loin depth were measured at d 130. 
2 Genetic backgrounds used were A×A (Duroc-based sire and dam), A×B, B×A, and B×B (synthetic line for the sire and dam primarily derived from 
Duroc, Pietrain, and Large White). 
3 Vaccine treatments included vaccinates (2 cc Circumvent PCV, Intervet Inc., Millsboro, Delaware) and nonvaccinated controls. Vaccine was ad-
ministered intramuscularly at 21 and 35 d of age. 
4 SE among treatment groups differed because of unbalanced design. In this table, the highest SE among the treatment groups was reported. 
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Figure 1.  Effect of PCV2 vaccination and time on indirect fluorescent antibody geometric 
mean titer (vaccine × time P < 0.01; a,b,c,d P < 0.01). 
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Figure 2.  Effect of PCV2 vaccination and time on PCV2 viral template quantity  
(a,b P < 0.01 within day). 
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Figure 3.  Distribution of off-test pig weights for control vs. vaccinated pigs of genetic 
background A×A. 
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Figure 4.  Distribution of off-test pig weights for control vs. vaccinated pigs of genetic 
background B×B. 
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